Could less immunotherapy be just as good for advanced nose cancer?
NCT ID NCT07373990
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial will test whether a shorter course of the immunotherapy drug tislelizumab, combined with chemotherapy and radiation, works as well as a longer course for people with advanced nasopharyngeal cancer. About 418 participants will be randomly assigned to receive either 3 or 5 cycles of tislelizumab after initial treatment. The main goal is to see if the shorter course is non-inferior in preventing cancer from returning or spreading.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tislelizumab (an immunotherapy drug)
What this could lead to
If successful, this could show that a shorter course of immunotherapy is just as effective as a longer one, reducing treatment burden for patients with advanced nasopharyngeal cancer.
What could go wrong
This is a non-inferiority trial, so the shorter course might prove slightly less effective. The study is not yet recruiting, and results will take years. Immunotherapy can cause immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••